Literature DB >> 20053912

Metabotropic glutamate receptor-mediated cell signaling pathways are altered in a mouse model of Huntington's disease.

Fabiola M Ribeiro1, Maryse Paquet, Lucimar T Ferreira, Tamara Cregan, Patrick Swan, Sean P Cregan, Stephen S G Ferguson.   

Abstract

Huntington's disease (HD) is an autosomal-dominant neurodegenerative disorder caused by a polyglutamine expansion in the huntingtin protein (Htt). Group I metabotropic glutamate receptors (mGluRs) are coupled to G(alphaq) and play an important role in neuronal survival. We have previously demonstrated that mGluRs interact with Htt. Here we used striatal neuronal primary cultures and acute striatal slices to demonstrate that mGluR-mediated signaling pathways are altered in a presymptomatic mouse model of HD (Hdh(Q111/Q111)), as compared to those of control mice (Hdh(Q20/Q20)). mGluR1/5-mediated inositol phosphate (InsP) formation is desensitized in striatal slices from Hdh(Q111/Q111) mice and this desensitization is PKC-mediated. Despite of decreased InsP formation, (S)-3,5-dihydroxylphenylglycine (DHPG)-mediated Ca(2+) release is higher in Hdh(Q111/Q111) than in Hdh(Q20/Q20) neurons. Furthermore, mGluR1/5-stimulated AKT and extracellular signal-regulated kinase (ERK) activation is altered in Hdh(Q111/Q111) mice. Basal AKT activation is higher in Hdh(Q111/Q111) neurons and this increase is mGluR5 dependent. Moreover, mGluR5 activation leads to higher levels of ERK activation in Hdh(Q111/Q111) than in Hdh(Q20/Q20) striatum. PKC inhibition not only brings Hdh(Q111/Q111) DHPG-stimulated InsP formation to Hdh(Q20/Q20) levels, but also causes an increase in neuronal cell death in Hdh(Q111/Q111) neurons. However, PKC inhibition does not modify neuronal cell death in Hdh(Q20/Q20) neurons, suggesting that PKC-mediated desensitization of mGluR1/5 in Hdh(Q111/Q111) mice might be protective in HD. Together, these data indicate that group I mGluR-mediated signaling pathways are altered in HD and that these cell signaling adaptations could be important for striatal neurons survival.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20053912      PMCID: PMC6632544          DOI: 10.1523/JNEUROSCI.4974-09.2010

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  43 in total

1.  Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery.

Authors:  Kathy Sengmany; Junaid Singh; Gregory D Stewart; P Jeffrey Conn; Arthur Christopoulos; Karen J Gregory
Journal:  Neuropharmacology       Date:  2016-07-05       Impact factor: 5.250

Review 2.  Regulation of GPCR activity, trafficking and localization by GPCR-interacting proteins.

Authors:  Ana C Magalhaes; Henry Dunn; Stephen Sg Ferguson
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Pyk2 uncouples metabotropic glutamate receptor G protein signaling but facilitates ERK1/2 activation.

Authors:  Alexander A Nicodemo; Macarena Pampillo; Lucimar T Ferreira; Lianne B Dale; Tamara Cregan; Fabiola M Ribeiro; Stephen S G Ferguson
Journal:  Mol Brain       Date:  2010-01-21       Impact factor: 4.041

4.  GRK2 targeted knock-down results in spontaneous hypertension, and altered vascular GPCR signaling.

Authors:  Elena Tutunea-Fatan; Fabiana A Caetano; Robert Gros; Stephen S G Ferguson
Journal:  J Biol Chem       Date:  2015-01-05       Impact factor: 5.157

5.  PET brain kinetics studies of (11)C-ITMM and (11)C-ITDM,radioprobes for metabotropic glutamate receptor type 1, in a nonhuman primate.

Authors:  Tomoteru Yamasaki; Jun Maeda; Masayuki Fujinaga; Yuji Nagai; Akiko Hatori; Joji Yui; Lin Xie; Nobuki Nengaki; Ming-Rong Zhang
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-04-25

Review 6.  Treatment of Huntington's disease.

Authors:  Samuel Frank
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

7.  Early down-regulation of PKCδ as a pro-survival mechanism in Huntington's disease.

Authors:  Laura Rué; Rafael Alcalá-Vida; Graciela López-Soop; Jordi Creus-Muncunill; Jordi Alberch; Esther Pérez-Navarro
Journal:  Neuromolecular Med       Date:  2013-07-30       Impact factor: 3.843

8.  Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.

Authors:  Melissa R Sarantos; Theodora Papanikolaou; Lisa M Ellerby; Robert E Hughes
Journal:  J Huntingtons Dis       Date:  2012

9.  Selective expression of mutant huntingtin during development recapitulates characteristic features of Huntington's disease.

Authors:  Aldrin E Molero; Eduardo E Arteaga-Bracho; Christopher H Chen; Maria Gulinello; Michael L Winchester; Nandini Pichamoorthy; Solen Gokhan; Kamran Khodakhah; Mark F Mehler
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-02       Impact factor: 11.205

10.  A novel target for Huntington's disease: ERK at the crossroads of signaling. The ERK signaling pathway is implicated in Huntington's disease and its upregulation ameliorates pathology.

Authors:  László Bodai; J Lawrence Marsh
Journal:  Bioessays       Date:  2012-02       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.